Benzinga | Feb 25, 2021 04:50PM EST

Cyclacel Pharmaceuticals Q4 EPS $(1.34) Misses $(0.51) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(0.51) by 162.75 percent. This is a 857.14 percent decrease over losses of $(0.14) per share from the same period last year.